Research ArticleFibrosis

Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis

See allHide authors and affiliations

Science Translational Medicine  05 Jun 2019:
Vol. 11, Issue 495, eaav5341
DOI: 10.1126/scitranslmed.aav5341

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Preventing peritoneal fibrosis

Peritoneal dialysis is used to treat patients with end-stage renal disease, but many of these patients develop peritoneal fibrosis that limits treatment efficacy. Si et al. studied cells from patients undergoing peritoneal dialysis and used a mouse model to understand the mechanism underlying progression of peritoneal fibrosis. They found that transforming growth factor β1 stimulated hyperglycolysis in mesothelial cells, contributing to a mesothelial-to-mesenchymal transition phenotype and peritoneal fibrosis. Manipulating the expression of three microRNAs using adeno-associated viruses could inhibit fibrosis in the mouse model, suggesting that correcting the altered metabolic state in mesothelial cells could be therapeutic for peritoneal fibrosis.

View Full Text